CN Bio’s PhysioMimix™ adopted by King’s College London to investigate chronic liver disease
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single and multi-organ microphysiological systems (MPS), today announced that King’s College London, an internationally renowned research university, has adopted the PhysioMimix™ Multi-Organ MPS.
FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications
CN Bio, a leading developer of single- and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the US Food and Drug Administration (FDA) has extended their research collaboration for a further three years.
CN Bio introduces the PhysioMimix™ OOC Multi-Organ Microphysiological System
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), has announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS.
CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip, today announced it has received a grant from Innovate UK, the UK’s innovation agency, to develop human-relevant MPS to advance investigations into SARS-CoV-2 infection.
CN Bio’s PhysioMimix technology receives FDA recognition
CN Bio, a leading developer of single and multi organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research with the US Food and Drug Administration (FDA)1.
CN Bio and University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients
CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients.
CN Bio to provide drug metabolism and safety toxicity testing services
CN Bio, a leading 3D cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced the commercial launch of its Drug Metabolism and Safety Toxicity Testing Services.
CN Bio and Imperial College London collaborate to identify novel treatments for alcoholic hepatitis
CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, has announced a collaboration with Imperial College London, a world-class research university. The research will harness CN Bio’s Liver-on-Chip technology to advance the understanding of the underlying mechanisms of alcoholic…
CN Bio makes key senior appointments to support international commercial development
CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced the appointments of James Craven as Chief Commercial Officer and Dr Brian Manning as US Head of Sales.
CN Bio and Cambridge University identify novel regulatory pathway driving NASH
CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research led by researchers at the University of Cambridge in Nature Metabolism1, identifying a novel pathway that regulates the underlying mechanism of Non-Alcoholic…
CN Bio Innovations raises $9 million USD (c. £6.9 million GBP)
CN Bio Innovations (CN Bio), a leading cell culture company that has developed organ-on-chip laboratory instruments to improve the accuracy and efficiency of drug discovery, today announced it has raised $9 million USD (circa £6.9 million GBP) investment, led by CITIC Securities Investment Co., Ltd., and supported by existing investor CN Innovations Holdings Ltd.